FBR Capital Markets Initiates Coverage on Keryx Biopharmaceuticals (KERX)
Analysts at FBR Capital Markets began coverage on shares of Keryx Biopharmaceuticals (NASDAQ:KERX) in a research report issued to clients and investors on Wednesday. The firm set a “market perform” rating on the stock.
Keryx Biopharmaceuticals (NASDAQ:KERX) traded up 1.58% during mid-day trading on Wednesday, hitting $16.76. 1,863,912 shares of the company’s stock traded hands. Keryx Biopharmaceuticals has a 52-week low of $8.29 and a 52-week high of $17.46. The stock has a 50-day moving average of $15.19 and a 200-day moving average of $14.84. The company’s market cap is $1.539 billion.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same quarter in the previous year, the company posted ($0.14) earnings per share. On average, analysts predict that Keryx Biopharmaceuticals will post $-0.89 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Mizuho cut their price target on shares of Keryx Biopharmaceuticals from $32.00 to $30.00 in a research note on Friday, August 8th. Analysts at HC Wainwright reiterated a “buy” rating on shares of Keryx Biopharmaceuticals in a research note on Friday, May 23rd. They now have a $19.00 price target on the stock. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $23.89.
Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.